Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine vs ECT in Treatment Resistant Depression
NCT03113968Phase 3Completed
- Start
- Apr 2017
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ketamine in major depressive disorder (MDD) (2 arms). Primary endpoint: Quick Inventory of Depressive Symptomatology-Self-Report Scale Response. Started Apr 2017; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03113968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113968.